Clinicopathological Prognostic Factors and Chemotherapeutic Outcome for Two Histopathological Types of Ampulla of Vater Adenocarcinoma

Tao Xia, Xiaosan Wu, Yiping Mou, Yunyun Xu, Yucheng Zhou, Chao Lu, Qicong Zhu, Weiwei Jin, Yuan ChenFrontiers in Oncology 2021 · DOI

Abstract

Adenocarcinoma of the ampulla of Vater (AAV) is a rare malignancy with distinct histological subtypes. This study investigates the clinical outcomes and prognostic factors for intestinal-type (INT) and pancreatobiliary-type (PB) AAV. Analysis of 47 patients revealed that PB-type tumors are associated with significantly poorer survival. Furthermore, prognostic biomarkers differ by subtype: serum CA 19-9 is critical for INT-type, while CEA is more predictive for PB-type. Notably, adjuvant chemotherapy did not significantly impact overall survival in this cohort.

Introduction

Ampulla of Vater Adenocarcinoma (AAV) accounts for approximately 0.2% of gastrointestinal cancers. Located at the junction of the bile and pancreatic ducts, these tumors exhibit heterogeneous biological behavior, often categorized into intestinal (INT) or pancreatobiliary (PB) histological subtypes. While surgical resection via pancreatoduodenectomy (PD) remains the primary treatment, long-term survival varies widely, and the role of adjuvant chemotherapy remains controversial.

Methods

A retrospective analysis was conducted on 47 AAV patients treated at Zhejiang Provincial People’s Hospital between 2015 and 2019. Most patients (95.7%) underwent Laparoscopic Pancreatoduodenectomy (LPD). Histological classification was performed using immunohistochemistry (IHC) to identify specific molecular markers.

  • Intestinal-type (INT): Identified by markers CDX2, CK20, and MUC2.
  • Pancreatobiliary-type (PB): Identified by markers MUC1, MUC5a, and CK7.
Figure 1: Identification of intestinal-type AAV using markers CDX2, MUC2, and CK20.

Survival probabilities were estimated using the Kaplan–Meier method, and independent risk factors were determined via Cox proportional hazards modeling.

Results

The study cohort comprised 53.2% INT-type and 46.8% PB-type cases.

Survival Outcomes

The overall 1-year and 3-year survival rates were 97.6% and 58.9%, respectively. A significant disparity in median survival was observed between subtypes: 37.7 months for INT-type versus 26.9 months for PB-type.

Subtype-Specific Prognostic Factors

The study identified a divergence in critical biomarkers for each subtype:

  • INT-type: Elevated CA 19-9 (>37 U/ml) and perineural invasion were significantly associated with poor prognosis.
  • PB-type: Elevated CEA and larger tumor size (>2.5 cm) were the primary predictors of reduced survival.
Figure 2: Identification of pancreatobiliary-type AAV using markers CK7, MUC1, and MUC5a.

Chemotherapy Efficacy

Approximately 42.2% of patients received adjuvant chemotherapy (primarily Oxaliplatin/Capecitabine or Gemcitabine-based). However, multivariable analysis indicated that chemotherapy was not significantly associated with improved long-term survival in this cohort.

Discussion

The findings underscore the necessity of histological subtyping in AAV management. The PB-type's more aggressive nature and the subtype-specific utility of CEA and CA 19-9 suggest that a "one-size-fits-all" approach to monitoring and treatment is inadequate. The lack of clear benefit from current adjuvant chemotherapy regimens highlights the need for more targeted, subtype-specific therapeutic strategies.

Conclusion

Histological subtype is a critical determinant of prognosis in AAV. Future clinical trials should stratify patients by subtype to develop more effective, personalized treatment protocols. Limitations of this study include its retrospective design and small sample size, necessitating larger multi-center studies to validate these findings.

Summary updated

Abstract

Pancreatobiliary-type ampullary tumors were associated with poor survival. Serum CA 19-9 in the intestinal-type and CEA in the pancreatobiliary-type were significantly associated with poor survival. Ajuvant chemotherapy could not predict the survival of AAV patients.
BibTeX
@inproceedings{xia2021clinicopathological,
  author = {Tao Xia and Xiaosan Wu and Yiping Mou and Yunyun Xu and Yucheng Zhou and Chao Lu and Qicong Zhu and Weiwei Jin and Yuan Chen},
  title = {{Clinicopathological Prognostic Factors and Chemotherapeutic Outcome for Two Histopathological Types of Ampulla of Vater Adenocarcinoma}},
  booktitle = {Frontiers in Oncology},
  year = {2021},
  doi = {10.3389/fonc.2021.616108},
}
Figure